1.Adipose-derived stromal vascular fraction improves tendon healing in rabbits.
Mehdi BEHFAR ; Farshid SARRAFZADEH-REZAEI ; Rahim HOBBENAGHI ; Nowruz DELIREZH ; Bahram DALIR-NAGHADEH
Chinese Journal of Traumatology 2011;14(6):329-335
OBJECTIVETo evaluate the potential effects of uncultured adipose-derived stromal vascular fraction on tendon healing.
METHODSTwenty five adult male New Zealand white rabbits weighing 2.5-3.0 kg were used. Five rabbits were used as donors of adipose tissue and the rest were divided into control and treatment groups. The injury model was completed by unilateral tenotomy through the middle one third of deep digital flexor tendon. Immediately after suture repair, either fresh stromal vascular fraction from enzymatic digestion of adipose tissue or placebo was intratendinously injected at tendon stumps in treatment and control groups, respectively. Immobilization with cast was continued for two weeks after surgery. Animals were sacrificed at eight weeks after surgery and tendons underwent histological, immunohistochemical, and mechanical evaluations. Statistical analyses of quantitative and qualitative data were assessed using one-way analysis of variance and Mann-Whitney U-test, respectively.
RESULTSHistological evaluations demonstrated superior fibrillar linearity and continuity, and decreased vascularity in treatment group indicated improved organization and remodeling of neotendons. Immunohistochemistry de- monstrated a significant increase in collagen I expression in treatment group. Ultimate load and energy absorption capacity were both significantly increased in cell-treated repairs compared with controls.
CONCLUSIONThe present study shows that intratendinous injection of uncultured adipose-derived stromal vascular fraction results in improved structural and mechanical properties of tendon repairs and it could be an effective modality for treating tendon injury.
Animals ; Biomechanical Phenomena ; Disease Models, Animal ; Orthopedic Procedures ; Rabbits ; Reconstructive Surgical Procedures ; Tendon Injuries ; surgery ; Tendons ; Wound Healing
2.Metabolomic profiling of embryo culture media in patients with repeated implantation failure during assisted reproductive technology cycles
Sheyda NAMI ; Azam GOVAHI ; Nabaa NAJJAR ; Samaneh GHASEMI ; Farshid REZAEI ; Fatemehsadat AMJADI ; Gholamreza TAHERIPAK
Clinical and Experimental Reproductive Medicine 2024;51(3):260-267
Objective:
This study investigated the metabolic status of the spent culture media from embryos of patients with repeated implantation failure (RIF) undergoing in vitro fertilization–intracytoplasmic sperm injection cycles in comparison with the embryos from healthy fertile women.
Methods:
Metabolite levels in spent culture media were assessed and compared between embryos from RIF patients (n=35) and oocyte donors as controls (n=15). Protein levels of insulin-like growth factor 1 (IGF-1) were determined using Western blotting. Concentrations of glucose, pyruvate, and lactate were measured using spectrophotometry. Ionic colorimetric assay kits were utilized to analyze the concentrations of sodium, chloride, calcium, and magnesium ions. High-performance liquid chromatography was employed to measure the concentrations of glutamic acid, aspartic acid, methionine, phenylalanine, and histidine.
Results:
Glucose consumption and lactate secretion were higher in the control group than in the RIF group. The magnesium concentration was significantly higher in the control group than in the RIF group, but glutamic acid and aspartic acid concentrations were lower in the control group than in the RIF patients (p<0.05). The levels of IGF-1, sodium, calcium, chloride, methionine, histidine, and phenylalanine did not show statistically significant differences between the two groups.
Conclusion
The metabolic profile of the culture medium of the embryos in the RIF group differed from that of the control group. These findings suggest potential factors that may affect implantation capacity in RIF patients and provide a new perspective on embryo selection.
3.Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience
Reza GHALEHTAKI ; Kasra KOLAHDOUZAN ; Guglielmo Niccolò PIOZZI ; Saeid REZAEI ; Zoha SHAKA ; Nima Mousavi DARZIKOLAEE ; Reyhaneh BAYANI ; Behnam BEHBOUDI ; Mahdi AGHILI ; Felipe COUÑAGO ; Azadeh SHARIFIAN ; Farzaneh BAGHERI ; Reza NAZARI ; Naeim NABIAN ; Mohammad BABAEI ; Mohsen Ahmadi TAFTI ; Mohammadsadegh FAZELI ; Farshid FARHAN
Radiation Oncology Journal 2024;42(4):273-280
Purpose:
Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials and Methods:
A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis. Patient characteristics, treatment regimens, down-staging rates, pathological response, and overall survival (OS) were evaluated.
Results:
Both T4a and T4b patients experienced down-staging following nCRT (36.6% and 6.2% respectively; p = 0.021). T4a patients exhibited a higher rate of pathological complete response (pCR) than T4b patients (13.3% in T4a vs. 0% in T4b; p = 0.122). After a median follow-up of 36 months, the OS and recurrence-free survival (RFS) of T4a patients were significantly higher compared to T4b patients (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.05–6.05, p = 0.038 for OS; HR = 2.32, 95% CI 1.09–4.92, p = 0.025 for RFS).
Conclusion
This study provides valuable insights into the effectiveness of nCRT in T4 rectal cancer patients. Although down-staging was observed in both T4a and T4b subgroups, achieving a pCR remains a challenge, particularly in T4b patients. Further research is needed to optimize treatment strategies and enhance pCR rates in T4 rectal cancer patients to improve oncologic outcomes.
4.Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience
Reza GHALEHTAKI ; Kasra KOLAHDOUZAN ; Guglielmo Niccolò PIOZZI ; Saeid REZAEI ; Zoha SHAKA ; Nima Mousavi DARZIKOLAEE ; Reyhaneh BAYANI ; Behnam BEHBOUDI ; Mahdi AGHILI ; Felipe COUÑAGO ; Azadeh SHARIFIAN ; Farzaneh BAGHERI ; Reza NAZARI ; Naeim NABIAN ; Mohammad BABAEI ; Mohsen Ahmadi TAFTI ; Mohammadsadegh FAZELI ; Farshid FARHAN
Radiation Oncology Journal 2024;42(4):273-280
Purpose:
Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials and Methods:
A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis. Patient characteristics, treatment regimens, down-staging rates, pathological response, and overall survival (OS) were evaluated.
Results:
Both T4a and T4b patients experienced down-staging following nCRT (36.6% and 6.2% respectively; p = 0.021). T4a patients exhibited a higher rate of pathological complete response (pCR) than T4b patients (13.3% in T4a vs. 0% in T4b; p = 0.122). After a median follow-up of 36 months, the OS and recurrence-free survival (RFS) of T4a patients were significantly higher compared to T4b patients (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.05–6.05, p = 0.038 for OS; HR = 2.32, 95% CI 1.09–4.92, p = 0.025 for RFS).
Conclusion
This study provides valuable insights into the effectiveness of nCRT in T4 rectal cancer patients. Although down-staging was observed in both T4a and T4b subgroups, achieving a pCR remains a challenge, particularly in T4b patients. Further research is needed to optimize treatment strategies and enhance pCR rates in T4 rectal cancer patients to improve oncologic outcomes.
5.Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience
Reza GHALEHTAKI ; Kasra KOLAHDOUZAN ; Guglielmo Niccolò PIOZZI ; Saeid REZAEI ; Zoha SHAKA ; Nima Mousavi DARZIKOLAEE ; Reyhaneh BAYANI ; Behnam BEHBOUDI ; Mahdi AGHILI ; Felipe COUÑAGO ; Azadeh SHARIFIAN ; Farzaneh BAGHERI ; Reza NAZARI ; Naeim NABIAN ; Mohammad BABAEI ; Mohsen Ahmadi TAFTI ; Mohammadsadegh FAZELI ; Farshid FARHAN
Radiation Oncology Journal 2024;42(4):273-280
Purpose:
Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials and Methods:
A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis. Patient characteristics, treatment regimens, down-staging rates, pathological response, and overall survival (OS) were evaluated.
Results:
Both T4a and T4b patients experienced down-staging following nCRT (36.6% and 6.2% respectively; p = 0.021). T4a patients exhibited a higher rate of pathological complete response (pCR) than T4b patients (13.3% in T4a vs. 0% in T4b; p = 0.122). After a median follow-up of 36 months, the OS and recurrence-free survival (RFS) of T4a patients were significantly higher compared to T4b patients (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.05–6.05, p = 0.038 for OS; HR = 2.32, 95% CI 1.09–4.92, p = 0.025 for RFS).
Conclusion
This study provides valuable insights into the effectiveness of nCRT in T4 rectal cancer patients. Although down-staging was observed in both T4a and T4b subgroups, achieving a pCR remains a challenge, particularly in T4b patients. Further research is needed to optimize treatment strategies and enhance pCR rates in T4 rectal cancer patients to improve oncologic outcomes.
6.Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience
Reza GHALEHTAKI ; Kasra KOLAHDOUZAN ; Guglielmo Niccolò PIOZZI ; Saeid REZAEI ; Zoha SHAKA ; Nima Mousavi DARZIKOLAEE ; Reyhaneh BAYANI ; Behnam BEHBOUDI ; Mahdi AGHILI ; Felipe COUÑAGO ; Azadeh SHARIFIAN ; Farzaneh BAGHERI ; Reza NAZARI ; Naeim NABIAN ; Mohammad BABAEI ; Mohsen Ahmadi TAFTI ; Mohammadsadegh FAZELI ; Farshid FARHAN
Radiation Oncology Journal 2024;42(4):273-280
Purpose:
Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials and Methods:
A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis. Patient characteristics, treatment regimens, down-staging rates, pathological response, and overall survival (OS) were evaluated.
Results:
Both T4a and T4b patients experienced down-staging following nCRT (36.6% and 6.2% respectively; p = 0.021). T4a patients exhibited a higher rate of pathological complete response (pCR) than T4b patients (13.3% in T4a vs. 0% in T4b; p = 0.122). After a median follow-up of 36 months, the OS and recurrence-free survival (RFS) of T4a patients were significantly higher compared to T4b patients (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.05–6.05, p = 0.038 for OS; HR = 2.32, 95% CI 1.09–4.92, p = 0.025 for RFS).
Conclusion
This study provides valuable insights into the effectiveness of nCRT in T4 rectal cancer patients. Although down-staging was observed in both T4a and T4b subgroups, achieving a pCR remains a challenge, particularly in T4b patients. Further research is needed to optimize treatment strategies and enhance pCR rates in T4 rectal cancer patients to improve oncologic outcomes.
7.Outcomes of neoadjuvant chemoradiotherapy in T4 rectal cancer patients: a real-world single institution experience
Reza GHALEHTAKI ; Kasra KOLAHDOUZAN ; Guglielmo Niccolò PIOZZI ; Saeid REZAEI ; Zoha SHAKA ; Nima Mousavi DARZIKOLAEE ; Reyhaneh BAYANI ; Behnam BEHBOUDI ; Mahdi AGHILI ; Felipe COUÑAGO ; Azadeh SHARIFIAN ; Farzaneh BAGHERI ; Reza NAZARI ; Naeim NABIAN ; Mohammad BABAEI ; Mohsen Ahmadi TAFTI ; Mohammadsadegh FAZELI ; Farshid FARHAN
Radiation Oncology Journal 2024;42(4):273-280
Purpose:
Treatment outcomes of locally advanced rectal cancer have improved significantly in recent decades. This retrospective study aimed to assess the efficacy of neoadjuvant chemoradiotherapy (nCRT) followed by surgery in patients with T4 rectal cancer and the different outcomes between T4a and T4b patients.
Materials and Methods:
A total of 60 clinically T4 rectal cancer patients who underwent nCRT were included in the analysis. Patient characteristics, treatment regimens, down-staging rates, pathological response, and overall survival (OS) were evaluated.
Results:
Both T4a and T4b patients experienced down-staging following nCRT (36.6% and 6.2% respectively; p = 0.021). T4a patients exhibited a higher rate of pathological complete response (pCR) than T4b patients (13.3% in T4a vs. 0% in T4b; p = 0.122). After a median follow-up of 36 months, the OS and recurrence-free survival (RFS) of T4a patients were significantly higher compared to T4b patients (hazard ratio [HR] = 2.52, 95% confidence interval [CI] 1.05–6.05, p = 0.038 for OS; HR = 2.32, 95% CI 1.09–4.92, p = 0.025 for RFS).
Conclusion
This study provides valuable insights into the effectiveness of nCRT in T4 rectal cancer patients. Although down-staging was observed in both T4a and T4b subgroups, achieving a pCR remains a challenge, particularly in T4b patients. Further research is needed to optimize treatment strategies and enhance pCR rates in T4 rectal cancer patients to improve oncologic outcomes.